Gossamer Bio/$GOSS
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
- Ticker
- $GOSS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 162
- Headquarters
- San Diego, United States
- Website
- www.gossamerbio.com
Gossamer Bio Metrics
BasicAdvanced
$77M
-
-$0.65
2.01
-
Price and volume
Market cap
$77M
Beta
2.01
52-week high
$3.87
52-week low
$0.11
Average daily volume
34M
Financial strength
Current ratio
0.528
Quick ratio
0.458
Long term debt to equity
-3.146
Total debt to equity
-42.612
Interest coverage (TTM)
-14.47%
Profitability
EBITDA (TTM)
-158.597
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-235.00%
Operating margin (TTM)
-297.67%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-62.39%
Return on equity (TTM)
178.72%
Valuation
Price to revenue (TTM)
0.75
Price to book
-0.82
Price to tangible book (TTM)
-0.82
Price to free cash flow (TTM)
-0.246
Free cash flow yield (TTM)
-407.08%
Free cash flow per share (TTM)
-0.641
Growth
Revenue change (TTM)
32.43%
Earnings per share change (TTM)
6.17%
3-year earnings per share growth (CAGR)
-33.41%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Gossamer Bio News
AllArticlesVideos
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Business Wire5 hours ago
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate
Benzinga4 weeks ago
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.